Eye health company Bausch + Lomb has issued a voluntary recall of a series of intraocular lenses, according to a March 27 report from Global Data.
The recall is associated with its enVista platform following a number of reports of toxic anterior segment syndrome cases by patients who had implanted enVista Envy IOLs, enVista Aspire and some enVista monofocal lenses.
TASS usually occurs 12 to 48 hours after eye surgery. All reported cases related to enVista have been treated without the need to remove implanted lenses.
The reports “represent an extremely small percentage of implanted lenses,” Bausch + Lomb CEO and chairman Brent Saunders told Global Data.
The enVista Aspire monofocal and toric IOLs with Intermediate Optimised optics were launched in the U.S. in 2023.